We are open to partnering, contact our team at
With a core focus on transforming the cancer immunotherapy field.
The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatment safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world’s largest markets.
We are actively seeking partners for our pipeline of ground-breaking programmes and are open to partnering discussions.
POLB 001 Clinical & Scientific Insights
Peer-Reviewed Publication
POLB 001, a p38 MAPK inhibitor, decreases local and systemic inflammatory responses in healthy volunteers
Frontiers in Immunology, 2025
Conference Abstract
POLB 001 reduces CRS in a mouse model of immunotherapy-induced cytokine release syndrome
ASH Annual Meeting 2024
KOL Perspective
Expert haematologist commentary on the CRS treatment landscape and unmet medical need
Prof. Gareth Morgan, NYU Langone“
These transformative therapies will continue to be restricted until there is a way to administer them more safely. POLB 001 holds great promise in tackling this issue.Dr Emma Searle, Consultant Haematologist, The Christie NHS Foundation Trust & Chief Investigator, TOPICAL trial
Collaborating with Poolbeg Pharma
“Once again, we’re pleased to see that leveraging CytoReason’s computational disease models to extract insights from Poolbeg’s unique human challenge data can optimise the target discovery process. More importantly, these impressive results would not be possible without the commitment, transparency, and reciprocity of both teams.”
David Harel
CEO of CytoReason
Neel S. Madhukar, PhD
CEO of OneThree Biotech
“We are very pleased to be working with Poolbeg and to have the opportunity to deploy the ATLANTIS platform to complete the first ever AI-driven analysis of RSV disease progression data. I am delighted that Poolbeg’s unique dataset combined with OneThree’s externally validated platform have now delivered new actionable insights surrounding disease biology and drug discovery that can bring much needed treatment options for both the young and the elderly; the most vulnerable to RSV infection.”